Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

hich should not be given to healthy volunteers, this evaluation is being done in previously untreated elderly patients with de novo poor-risk AML who receive Cloretazine(R) (VNP40101M) therapy.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and f
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015  New York College of Health Professions announces ... portfolio with U.S. Patent #8,996,098 donated by its Chairman ... a surgical instrument that allows surgeons to view and ... in the traditional format of a slide that is ... during surgery, thus providing the surgeon real time analysis ...
(Date:4/1/2015)... and MOUNTAIN VIEW, Calif. , ... BSX ) announces that it has signed ... venture-backed medical device company that develops, manufactures and ... guided transluminal drainage of targeted areas within the ... this week. The Xlumena portfolio ...
(Date:4/1/2015)... April 1, 2015  The first national study ... supplements to treat attention-deficit/hyperactivity disorder (ADHD) among children ... of children with ADHD were receiving behavioral therapy ... Control and Prevention (CDC) study, "Treatment of Attention-Deficit/Hyperactivity ... published today in The Journal of Pediatrics ...
Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3Boston Scientific Agrees to Acquire Xlumena 2Boston Scientific Agrees to Acquire Xlumena 3Boston Scientific Agrees to Acquire Xlumena 4Boston Scientific Agrees to Acquire Xlumena 5CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 2CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 3CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 4
... YORK, Dec. 29, 2010 Reportlinker.com announces that a ... Regenerative Medicine Markets ... way of treating injured and diseased human tissue by ... As such, astounding new advancements in the ability to ...
... 2010 Reportlinker.com announces that a new market ... 2010-2015 In-depth Research Report on China ... Report SummaryBased on the ... General Administration of Custom, Ministry of Commerce , ...
Cached Medicine Technology:Reportlinker Adds Regenerative Medicine Markets 2Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry 2
(Date:4/1/2015)... April 01, 2015 BioPlus Specialty ... specialty pharmacies, has released a new app to keep ... for treating chronic hepatitis C virus (HCV) infection. This ... on information from the American Association for the Study ... , Numerous new direct-acting oral medications to treat HCV ...
(Date:4/1/2015)... 01, 2015 Dr Roz Kamani, a ... is now offering her patients an opportunity to learn ... participate in “Beauty Days”, which is an exclusive VIP ... Kamani’s Kitsilano Skin Care Clinic. It is attended by ... about the latest products and services that are on ...
(Date:4/1/2015)... South Florida’s newest concept in retirement ... (PCOA) approval from the State of Florida. This ... of a retirement community that will offer a catered ... development. , America’s aging population is experiencing unprecedented growth ... of seniors, according to a recent report by Harvard’s ...
(Date:4/1/2015)... April 01, 2015 Health Advocate™, Inc., ... a subsidiary of West Corporation, today launched its new ... http://blog.healthadvocate.com and through the Health Advocate member website, ... get, and stay, healthy. , “We’re pleased to introduce ... the public,” said Martin Rosen, Executive Vice President, Health ...
(Date:4/1/2015)... Atlanta, GA (PRWEB) April 01, 2015 ... Emergency Medicine Practice, Pediatric Emergency Medicine Practice, and ... it has partnered with AgileMD to provide the ... Practice , in a mobile application format available ... , “Our collaboration with AgileMD to develop ...
Breaking Medicine News(10 mins):Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Casa Sant’Angelo Receives Approval for New Retirement Living 2Health News:Health Advocate Launches New Health and Wellness Blog 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3
... ... leader in call tracking, performance analysis, sales and management training, announced that its non-profit ... loss in a Super Bowl Hearing Mission on Wednesday, February 3rd, from noon – ... ...
... , DETROIT , Jan. 29 ... , M.D., Ph.D., has been named the new president and ... A thoracic oncologist, Dr. Bepler will begin his new position ... ) , In addition to his chief administrative duties, ...
... advance development of facial recognition systems, study authors suggest , ... recognize human faces, as long as they think the faces ... series of experiments, researchers from Australia and France determined that ... were rewarded with a sweet treat for doing so. , ...
... ... Health Problems Looks to Interactive Agency for Website Support , ... St. Louis, MO (PRWEB) January 29, 2010 -- The ... partnership with the Karla Smith Foundation (KSF), an organization focused on working to provide support ...
... ... of water-borne diseases from contaminated water, DynGlobal deploys its DG 24/7 water purification systems ... purification units will be installed throughout the nation as permanent potable water sources for ... ...
... ... Bone marrow is a leading source of adult stem cells, which are ... an arduous and often painful process. Now, researchers have found evidence that ... of valuable and easy-to-obtain regenerative cells called hematopoietic stem and progenitor cells ...
Cached Medicine News:Health News:CallSource joins Starkey Hearing Foundation to Tackle Children's Hearing Loss in Super Bowl Mission 2Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 2Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 3Health News:Karmanos Cancer Institute in Detroit Names Gerold Bepler, M.D., Ph.D., as CEO 4Health News:The Net Impact is Proud to Announce Partnership with the Karla Smith Foundation 2Health News:The Net Impact is Proud to Announce Partnership with the Karla Smith Foundation 3Health News:The Net Impact is Proud to Announce Partnership with the Karla Smith Foundation 4Health News:DynGlobal and Project Hope Partner to Bring Permanent Clean Water Solutions to Devastated Haiti 2Health News:DynGlobal and Project Hope Partner to Bring Permanent Clean Water Solutions to Devastated Haiti 3Health News:Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 2Health News:Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 3Health News:Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 4
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,408-9) or contact custom...
... ergonomic design reduces hand fatigue, prevents injury. Dry seal technology. No cleaning, ... 1-10 Inaccuracy (%) ... Imprecision(%) ... 0.1 Dimensions: ...
... Pipetman Ultra is a fully adjustable, ... display. It is the latest member of ... same characteristics: robustness, accuracy, and precision. We ... on feedback from our customers. Eight models ...
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 2-20 microliter range....
Medicine Products: